Elanco Animal Health Incorporated Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
Elanco Animal Health Incorporated (ELAN) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $161.00 million as of 2022-12-31, per its 10-K filed 2023-03-01.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2023-03-01
- 2022-12-31: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $161.00M.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2022-12-31 | $161.00M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |